Reuters logo
BRIEF-TG Therapeutics, Inc. announces investigator initiated trial to study TGR-1202
January 4, 2017 / 12:36 PM / 9 months ago

BRIEF-TG Therapeutics, Inc. announces investigator initiated trial to study TGR-1202

Jan 4 (Reuters) - Tg Therapeutics Inc :

* Tg therapeutics, inc. Announces investigator initiated trial at the university of nebraska medical center to study tgr-1202 in combination with ibrutinib in patients with relapsed or refractory diffuse large b-cell lymphoma

* TG Therapeutics inc says tg therapeutics and janssen pharmaceuticals will each provide drug and equally share study-related costs

* Tg therapeutics inc says Phase 2 study will evaluate safety and efficacy of combination of tgr-1202 and ibrutinib Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below